Pacira Pharmaceuticals Debt to Equity Ratio:
0.3825 for Dec. 31, 2012Pacira Pharmaceuticals Historical Debt to Equity Ratio Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| Dec. 31, 2012 | 0.3825 |
| Sept. 30, 2012 | 0.3099 |
| June 30, 2012 | 0.261 |
| March 31, 2012 | 0.6712 |
| Dec. 31, 2011 | 0.5299 |
| Sept. 30, 2011 | 1.836 |
| June 30, 2011 | 1.100 |
| March 31, 2011 | 0.8071 |
About Debt to Equity Ratio
Leverage ratio indicating the relative proportion of shareholders' equity and debt used to finance a company's assets. A low debt to equity ratio indicates lower risk, because debt holders have less claims on the company's assets. A debt to equity ratio of 5 means that debt holders have a 5 times more claim on assets than equity holders.
A high debt to equity ratio usually means that a company has been aggressive in financing growth with debt and often results in volatile earnings.
It is also known as Debt/Equity Ratio, Debt-Equity Ratio, and D/E Ratio.
Learn More
PCRX Debt to Equity Ratio Benchmarks
| Companies | |
|---|---|
| BioScrip | 0.7715 |
| Neurocrine Biosciences | 0.00 |
| Lannett Company | 0.0586 |
PCRX Debt to Equity Ratio Rankings
| Overall |
66th percentile 2717 of 8002 |
| Sector |
43rd percentile 385 of 684 in Healthcare |
| Industry |
44th percentile 30 of 54 in Drug Manufacturers - Major |
PCRX Debt to Equity Ratio Range, Past 5 Years
| Minimum | 0.2610 | Jun 2012 |
| Maximum | 1.836 | Sep 2011 |
| Average | 0.7372 |
PCRX News
Pacira Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Seeking Alpha May 8
Seeking Alpha May 8
